Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib Alone and in Combination with Paclitaxel in Advanced Nonhematologic Malignancies
NCT02412722Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapanisertib in Non-hematologic malignancy (6 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 15 months, Geometric Mean Ratio of Cmax: Maximum Observed Plasma Concentration of Sapanisertib Milled API Capsules Under Fasted and Fed Conditions and 5 more. Started Mar 2015; status: completed.
02
Drugs
sapanisertib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NCT02412722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412722.